Radafaxine

Radafaxine
Clinical data
Other names	(S,S)-Hydroxybupropion; (2S,3S)-Hydroxybupropion; GW-353,162
Routes of; administration	Oral
ATC code	none;
Identifiers
	IUPAC name (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol;
CAS Number	192374-14-4 ; HCl: 106083-71-0 ;
PubChem CID	9795056;
ChemSpider	7970823 ;
UNII	Q47741214K; HCl: SYD411HZ3S ;
ChEMBL	ChEMBL1172928 ;
CompTox Dashboard (EPA)	DTXSID501318447 ;
Chemical and physical data
Formula	C13H18ClNO2
Molar mass	255.74 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cccc(c1)[C@]2(O)OCC(N[C@H]2C)(C)C;
	InChI InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1 ; Key:RCOBKSKAZMVBHT-TVQRCGJNSA-N ;
	(what is this?) (verify)

Radafaxine (developmental code GW-353,162; also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion) is a norepinephrine–dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to "poor test results".

Clinical data

Other names	(S,S)-Hydroxybupropion; (2S,3S)-Hydroxybupropion; GW-353,162
Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
CAS Number	192374-14-4^Y HCl: 106083-71-0^Y
PubChem CID	9795056
ChemSpider	7970823^Y
UNII	Q47741214K HCl: SYD411HZ3S^Y
ChEMBL	ChEMBL1172928^Y
CompTox Dashboard (EPA)	DTXSID501318447
Chemical and physical data
Formula	C₁₃H₁₈ClNO₂
Molar mass	255.74 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Clc1cccc(c1)[C@]2(O)OCC(N[C@H]2C)(C)C
InChI InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1^Y Key:RCOBKSKAZMVBHT-TVQRCGJNSA-N^Y
^NY (what is this?) (verify)